The combined actions of these two agents increase Bax expression, inhibit Bcl-2 levels, and downregulate the phosphorylation of ERK and Akt, collectively suppressing prostate cancer progression and promoting apoptosis. Here, AKT1 is linked to prostate carcinoma.